| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.1992.10.1.95 |
| P953 | full work available at URL | http://intl.jco.org/cgi/content/abstract/10/1/95 |
| https://ascopubs.org/doi/pdfdirect/10.1200/JCO.1992.10.1.95 | ||
| P698 | PubMed publication ID | 1727929 |
| P2093 | author name string | H. Kobayashi | |
| T. Terao | |||
| Y. Kawashima | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | oncology | Q162555 |
| carbohydrate tumor-associated antigens | Q77299973 | ||
| ovarian cancer | Q172341 | ||
| P304 | page(s) | 95-101 | |
| P577 | publication date | 1992-01-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer | |
| P478 | volume | 10 |
| Q36138929 | A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer |
| Q54361569 | A rat model to study the role of STn antigen in colon cancer. |
| Q70620538 | A simple, noninvasive, sensitive method for diagnosis of amniotic fluid embolism by monoclonal antibody TKH-2 that recognizes NeuAc alpha 2-6GalNAc |
| Q40807523 | Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer |
| Q90600562 | Breast cancer cells expressing cancer-associated sialyl-Tn antigen have less capacity to develop osteolytic lesions in a mouse model of skeletal colonization |
| Q54385315 | Cancer Vaccines in Ovarian Cancer: How Can We Improve? |
| Q74033284 | Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 |
| Q73934556 | Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine |
| Q22010719 | Cloning and expression of a human gene encoding an N-acetylgalactosamine-alpha2,6-sialyltransferase (ST6GalNAc I): a candidate for synthesis of cancer-associated sialyl-Tn antigens |
| Q35590300 | Commensal ocular bacteria degrade mucins |
| Q36079919 | Correlation between sialyl Tn antigen and lymphatic metastasis in patients with Borrmann type IV gastric carcinoma |
| Q53435760 | Different modes of sialyl-Tn expression during malignant transformation of human colonic mucosa. |
| Q38828915 | Efficient chemoenzymatic synthesis of sialyl Tn-antigens and derivatives |
| Q35745593 | Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model. |
| Q40982361 | Enzymatic basis for sialyl-Tn expression in human colon cancer cells |
| Q42590635 | Expression of sialyl-Tn in gastric cancer: correlation with known prognostic factors |
| Q41851439 | Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer |
| Q94547625 | Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers |
| Q64105045 | From "Serum Sickness" to "Xenosialitis": Past, Present, and Future Significance of the Non-human Sialic Acid Neu5Gc |
| Q30658777 | Glycosylations versus conformational preferences of cancer associated mucin core |
| Q26752363 | Hallmarks of glycosylation in cancer |
| Q35878762 | Human urinary glycoproteomics; attachment site specific analysis of N- and O-linked glycosylations by CID and ECD |
| Q34900010 | Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. |
| Q64998216 | Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma. |
| Q92859820 | I-branched carbohydrates as emerging effectors of malignant progression |
| Q70577158 | Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant |
| Q71729275 | Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients |
| Q35213250 | Immunologic principles and immunotherapeutic approaches in ovarian cancer |
| Q73486633 | Immunoreactivities of polyclonal and monoclonal anti-T and anti-Tn antibodies with human carcinoma cells, grownin vitro and in a xenograft model |
| Q48028076 | Immunotherapy and breast cancer |
| Q36868822 | Improving the antigenicity of sTn antigen by modification of its sialic acid residue for development of glycoconjugate cancer vaccines |
| Q35817496 | Integrative network analysis for survival-associated gene-gene interactions across multiple genomic profiles in ovarian cancer. |
| Q37592596 | Involvement of a non-human sialic Acid in human cancer |
| Q38570769 | MUC1 (CD227): a multi-tasked molecule |
| Q50047316 | Monophosphoryl Lipid A (MPL) as an Adjuvant for Anti-Cancer Vaccines: Clinical Results |
| Q35978268 | Mucin-associated sialosyl-Tn antigen expression in gastric cancer correlates with an adverse outcome |
| Q41725563 | New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins |
| Q33783697 | Pathways of O-glycan biosynthesis in cancer cells |
| Q35584716 | Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer |
| Q35692128 | Probing the O-glycoproteome of gastric cancer cell lines for biomarker discovery. |
| Q49293633 | Prognostic significance of ST6GalNAc-1 expression in patients with non-metastatic clear cell renal cell carcinoma |
| Q71089023 | Prognostic value of preoperative immunosuppressive acidic protein in patients with gastric carcinoma. Findings from three independent clinical trials. Tumor Marker Committee for the Study Group of Immunochemotherapy with PSK for Gastric Cancer |
| Q38926234 | RNAi-mediated gene silencing of ST6GalNAc I suppresses the metastatic potential in gastric cancer cells |
| Q49179521 | ST6GALNAC1 plays important roles in enhancing cancer stem phenotypes of colorectal cancer via the Akt pathway |
| Q47863731 | Salivary gland carcinomas: prognostic significance of simple mucin-type carbohydrate antigens |
| Q51040072 | Sialyl Tn antigen is an independent predictor of outcome in patients with gastric cancer. |
| Q77063644 | Sialyl-Tn antigen as a useful predictor of poor prognosis in patients with advanced stomach cancer |
| Q33649572 | Sialyl-tn in cancer: (how) did we miss the target? |
| Q38366325 | Simple sugars to complex disease--mucin-type O-glycans in cancer |
| Q73701468 | Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes |
| Q41285973 | Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC-1 derived peptides |
| Q41809862 | Synthetic and Immunological Studies of sTn Derivatives Carrying 5-N-(p-Substituted Phenylacetyl)Sialic Acid for the Development of Effective Cancer Vaccines |
| Q37120643 | Synthetic and immunological studies of 5'-N-phenylacetyl sTn to develop carbohydrate-based cancer vaccines and to explore the impacts of linkage between carbohydrate antigens and carrier proteins |
| Q38197051 | The Cosmc connection to the Tn antigen in cancer |
| Q40665755 | The cell-specific expression of glycan antigens exemplified by the deficiency of beta 1,3 galactosyltransferase in the Tn-syndrome |
| Q108768848 | The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans |
| Q73954438 | The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy |
| Q38811520 | The role of glycans in the development and progression of prostate cancer |
| Q33643173 | Therapeutic aspects of polymorphic epithelial mucin in adenocarcinoma |
| Q55167285 | Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau. |
| Q28367459 | Tumor cells express FcgammaRI which contributes to tumor cell growth and a metastatic phenotype |
| Q35554103 | Tumor-Associated Carbohydrate Antigens Defining Tumor Malignancy: Basis for Development of Anti-Cancer Vaccines |
| Q37512647 | Tumor-associated glycans and their role in gynecological cancers: accelerating translational research by novel high-throughput approaches |
Search more.